Study on the Improvement of Microcirculation in Patients With Sepsis by Vitamin B6, Vitami
Sepsis is a kind of disease with high morbidity and mortality in ICU. At present, there is no specific treatment, and its pathogenesis is mainly excessive oxidative stress. Anti-inflammatory, antioxidant and immune-regulating drugs may produce better therapeutic effects, while vitamin B6, vitamin B12 and vitamin C have
| Condition(s) | Septic Shock |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Sepsis is a kind of disease with high morbidity and mortality in ICU. At present, there is no specific treatment, and its pathogenesis is mainly excessive oxidative stress. Anti-inflammatory, antioxidant and immune-regulating drugs may produce better therapeutic effects, while vitamin B6, vitamin B12 and vitamin C have anti-inflammatory, antioxidant and immune-regulating effects. The purpose of this study was to investigate whether vitamin B6, vitamin B12 combined with vitamin C can improve the microcirculation and organ dysfunction in patients with sepsis, and improve the survival rate of patients with sepsis. The study included 296 patients who met the inclusion criteria. After randomization, the experimental group was given intravenous vitamin B6 300mg qd in addition to the basic treatm |
| Who can participate | Inclusion Criteria: 1. Age ≥18 and \< 85 years old 2. Admitted to ICU 3. Diagnosis of patients with SEPSIS 3.0 (diagnostic criteria) 4, SOFA score is 2-13 points 5\. Obtain the informed consent of the subject or his family Exclusion Criteria: 1. Patients have absolute contraindications such as vitamin allergy 2. Patients with a history of gout 3. Death is expected within 24 hours 4. Pregnant women 5. Use hydroprednisone or other equivalent dose hormones \> 200mg/d within 24 hours 6. Without the informed consent of the patient or his/her representative 7. Patients with a history of scleroderma 8. Patients with a history of vasculitis 9. Patients with oral mucosal diseases 10. Patients with severe difficulty in opening their mouth and unable to detect sublingual microcirculation |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Lead sponsor | Fan Zeng |
| Locations | Chengdu, Sichuan, China |
| Start date | 2025-02-10 |
| NCT ID | NCT06749756 |
| Official listing | https://clinicaltrials.gov/study/NCT06749756 |